Immune monitoring data in 3rd quarter of CY 2013 Howard, PhD appointed as a non-executive directorĬAN-003: upcoming data for all 63 patients: Japanese method of use patent for CVac granted
#Oziexplorer 3.95.6e serial trial
Jeffrey Goh will deliver the presentationĬontinued rollout of the CAN-004 trial the ∼ANVAS studyĪnnounced plans to launch three exploratory, phase 2 trials of CVac for the treatment of resectable pancreatic, triple-negative breast, and metastatic colorectal cancers Primas clinical and manufacturing development plansĬAN-003 (phase 2 ovarian cancer trial) abstractĪccepted for oral presentation at the European Cancer Congress on October 1st in Amsterdam. Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.Īpproximately A$7.71 million received during the share purchase plan and options entitlement offer to help continue This presentation should not be relied on as a recommendation orįorecast by Prima BioMed. Because actual results could differ materially to assumptions made and PrimaīioMeds current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution. Importantįactors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks. Number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside Prima BioMeds control. Any forward looking statements in this presentation have been prepared on the basis of a No representation or warranty is made as to the accuracy, completeness or reliability of the information. Sources that have not been independently verified. The views expressed in this presentation contain information derived from publicly available Please contact Prima BioMed and/or refer to the Companys website for further Should be read in conjunction with past and future announcements made by Prima BioMed and should not be relied upon as an independent source of information. Accordingly, these slides and the information they contain These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification.
#Oziexplorer 3.95.6e serial update
The purpose of the presentation is to provide an update of the business of Prima BioMed Ltd ACN 009 237 889 (ASX:PRR Supplemental information to management discussion August 6, 2013
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
If Yes is marked, indicate below the file numberĪssigned to the registrant in connection with Rule 12g3-2(b): Not applicable. Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b) (1): ¨ Indicate by check mark whether the registrant files or will file annual reports under cover of Form
0 kommentar(er)
